drugset / Trial / NCT00923091
Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension
RandomizedParallel-groupTriple-blindTreatment
Summary
This study is to determine the change in blood pressure from the administration of Olmesartan/Amlodipine/Hydrochlorothiazide triple combinations compared to dual combinations with Olmesartan/Amlodipine.
Timeline
- Start
- 2009-06
- Primary completion
- 2011-01
- Completion
- 2011-03
Publications
- Marques da Silva P, Haag U, Guest JF, Brazier JE, Soro M. Health-related quality of life impact of a triple combination of olmesartan medoxomil, amlodipine besylate and hydrochlorotiazide in subjects with hypertension. Health Qual Life Outcomes. 2015 Feb 21;13:24. doi: 10.1186/s12955-015-0216-6.
- Volpe M, de la Sierra A, Ammentorp B, Laeis P. Open-label study assessing the long-term efficacy and safety of triple olmesartan/amlodipine/hydrochlorothiazide combination therapy for hypertension. Adv Ther. 2014 May;31(5):561-74. doi: 10.1007/s12325-014-0117-9. Epub 2014 Apr 24.
- Volpe M, Christian Rump L, Ammentorp B, Laeis P. Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination. Clin Drug Investig. 2012 Oct 1;32(10):649-64. doi: 10.1007/BF03261919.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amlodipine | Other / unclassified | 5 mg | Oral |
| Subject | Amlodipine | Other / unclassified | 10 mg | Oral |
| Subject | Hydrochlorothiazide | Unknown | 12.5 mg | — |
| Subject | Hydrochlorothiazide | Unknown | 25 mg | — |
| Subject | Olmesartan medoxomil | Unknown | 20 mg | Oral |
| Subject | Olmesartan medoxomil | Unknown | 40 mg | Oral |